Acute effects of tertatolol and nadolol on systemic and renal hemodynamics in patients with essential hypertension.
The acute systemic and renal hemodynamic effects of tertatolol, a new noncardioselective beta-blocker without partial agonist activity, were compared to those of an equipotent dose of nadolol in eight patients with essential hypertension. Tertatolol (5 mg) or nadolol (80 mg) were administered orally at an interval of 1 week in a random order as a double-blind, cross-over study. Cardiac output was measured by Doppler echography, and renal blood flow and glomerular filtration rate were measured by constant infusion techniques using 123I-iodohippurate and 51CR-EDTA, respectively. Measurements were performed before and then successively 2 and 4 hours after ingestion of the drugs. Both nadolol and tertatolol decreased blood pressure and cardiac output to a comparable extent. Renal blood flow remained unchanged, so that the renal fraction of cardiac output increased from 14.4 +/- 1.5% to 21.3 +/- 2% after nadolol and from 14.8 +/- 2.4% to 20.5 +/- 1.8% after tertatolol (mean +/- SE, P less than 0.01 before vs. after; nadolol vs. tertatolol was not significant). The glomerular filtration rate remained unchanged, from 68 +/- 9 to 64 +/- 6 mL/min.m2 after nadolol and from 71 +/- 8 to 67 +/- 7 mL/min.m2 after tertatolol (before vs. after and nadolol vs. tertatolol levels were not significant). These results show that both tertatolol and nadolol redistribute cardiac output to the kidneys in patients with essential hypertension.
Degaute
J P
JP
Department of Intensive Care, Erasme University Hospital, Brussels, Belgium.
Naeije
R
R
Abramowicz
M
M
Leeman
M
M
Schoutens
A
A
Prost
J F
JF
D000328:Adult; D002302:Cardiac Output / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009248:Nadolol / Q000097:blood / Q000627:therapeutic use*; D011412:Propanolamines / Q000097:blood / Q000627:therapeutic use*; D012079:Renal Circulation / Q000187:drug effects*; D013876:Thiophenes; D014655:Vascular Resistance / Q000187:drug effects
D011412:Propanolamines; D013876:Thiophenes; D009248:Nadolol; C005632:tertatolol